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Neurodegenerative diseases are among the leading causes of disability and death
worldwide. The disease-related socioeconomic burden is expected to increase with the
steadily increasing life expectancy. In spite of decades of clinical and basic research,
most strategies designed to manage degenerative brain diseases are palliative.
This is not surprising as neurodegeneration progresses “silently” for decades before
symptoms are noticed. Importantly, conceptual models with heuristic value used to
study neurodegeneration have been constructed retrospectively, based on signs and
symptoms already present in affected patients; a circumstance that may confound
causes and consequences. Hence, innovative, paradigm-shifting views of the etiology
of these diseases are necessary to enable their timely prevention and treatment. Here,
we outline four alternative views, not mutually exclusive, on different etiological paths
toward neurodegeneration. First, we propose neurodegeneration as being a secondary
outcome of a primary cardiovascular cause with vascular pathology disrupting the
vital homeostatic interactions between the vasculature and the brain, resulting in
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cognitive impairment, dementia, and cerebrovascular events such as stroke. Second,
we suggest that the persistence of senescent cells in neuronal circuits may favor,
together with systemic metabolic diseases, neurodegeneration to occur. Third, we
argue that neurodegeneration may start in response to altered body and brain trophic
interactions established via the hardwire that connects peripheral targets with central
neuronal structures or by means of extracellular vesicle (EV)-mediated communication.
Lastly, we elaborate on how lifespan body dysbiosis may be linked to the origin of
neurodegeneration. We highlight the existence of bacterial products that modulate the
gut-brain axis causing neuroinflammation and neuronal dysfunction. As a concluding
section, we end by recommending research avenues to investigate these etiological
paths in the future. We think that this requires an integrated, interdisciplinary conceptual
research approach based on the investigation of the multimodal aspects of physiology
and pathophysiology. It involves utilizing proper conceptual models, experimental animal
units, and identifying currently unused opportunities derived from human data. Overall,
the proposed etiological paths and experimental recommendations will be important
guidelines for future cross-discipline research to overcome the translational roadblock
and to develop causative treatments for neurodegenerative diseases.
Keywords: lifespan, vascular pathology, senescence, body–brain trophism, dysbiosis
INTRODUCTION
Neurological disorders are the leading cause of disability-adjusted
life-years and the second-leading cause of deaths worldwide.
This burden has increased substantially over the past 25 years
because of expanding population numbers and aging (GBD
2015 Neurological Disorders Collaborator Group, 2017) and will
continue to grow in the coming decades due to the further
increase in life expectancy.
At intermediate and advanced stages, frequently by the time
a diagnosis is made, neurodegeneration has affected higher
brain areas that control cognitive, sensory, and motor functions.
Because the majority of cases are seen by the age of 50
or older in both men and women, many scientists think of
neurodegenerative diseases as processes that reflect abnormal
aging. Likewise, since neurodegeneration involves the loss of
neuronal populations brain-wide, many researchers believe
that neuronal death results from altered processes intrinsic
to the nervous system, such as neuroinflammation, abnormal
accumulation or deteriorated clearance of toxic proteins, and
reduced anti-oxidative defenses.
Hence, current explicative models of neurodegenerative
diseases account for signs and symptoms already seen in affected
patients. In fact, the majority of these causative models have
been formulated in retrospect, based on what is already present
in the patient’s brain. Given the nature of these models, it
is difficult to identify real causes from mere consequences
and epiphenomena. This is even more puzzling given that
neurodegenerative diseases are life-spanning processes that start
silently at least 20 to 30 years before the pathological signs
and symptoms are recognized by patients and diagnosed by
physicians. In addition, accumulating information suggests an
extraneural origin of neurodegeneration.
Clearly, the essential premises guiding research on
neurodegenerative diseases seem at least partly incorrect
and somewhat misleading. This may explain why, despite
researchers’ best efforts, neurodegeneration is still a growing
health concern and the reason why therapeutic measures are
currently palliative, while preventive approaches are often
ineffective (Crous-Bou et al., 2017; Hsu and Marshall, 2017;
Klein and Tyrlikova, 2017).
Here, we outline four different paths as the basis for a
paradigm shift toward an etiologic view on neurodegeneration:
(1) the vascular origin of neurodegeneration, (2) cellular
senescence as the origin of neurodegeneration, (3) body–brain
trophic interactions as the origin of neurodegeneration, and
(4) lifespan gut dysbiosis as the origin of neurodegeneration.
We did not cover here genetic components as risk factors
for neurodegeneration, a comprehensive analysis of which can
be found elsewhere (Brainstorm et al., 2018). We provide
concrete recommendations on how to investigate the discussed
etiological paths experimentally in future studies. This work is
the result of the discussions that took place during the German-
Mexican Roundtable Exploring New Etiological Paths Towards
Neurodegeneration in October 2018.
THE VASCULAR ORIGIN OF
NEURODEGENERATION
Neurons depend on blood vessels to deliver oxygen and nutrients,
for the removal of carbon dioxide and other by-products of
metabolism from the brain’s interstitial space, which helps to
maintain the homeostasis of the cerebral microenvironment.
Therefore, to function properly, it is thought that the cerebral
circulation has developed adaptive mechanisms to provide the
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trophic molecules and energy substrates needed for neuronal
cells at different times and regions, depending on neural activity
(Girouard and Iadecola, 2006).
The recognition of these mechanisms led to the concept
of neurovascular coupling (Roy and Sherrington, 1890), which
refers to the dynamic functional change in cerebral blood flow
that occurs in response to local neuronal activity (Dirnagl, 1997;
Kisler et al., 2017; Villringer, 1997). This response increases
cerebral blood flow within the activated brain regions to fulfill
energy demands in a process known as functional hyperemia.
The main players of these dynamic adjustments in the cerebral
blood flow are neurons, glia, and vascular cells. All of them
come together in a functional morphological entity termed the
“neurovascular unit”. This view explains why cerebrovascular
diseases linked to neurodegeneration are considered as stand-
alone etiopathological states (Przedborski et al., 2003; Brown
et al., 2005). Vascular diseases, however, may be the forerunners
of neurodegeneration. In support of this, it has been shown that
shifts in blood pressure lead neurons to adjust the excitability
thresholds according to brain perfusion levels, safeguarding
their homeostasis. Hence, vascular diseases may occur first and
then later neurodegeneration may follow, if the process of
neurovascular coupling proceeds ineffectively (Moore and Cao,
2008; Kim et al., 2016).
Cerebral blood vessels originate from large cerebral arteries
arising from the circle of Willis. As they find the way through
the brain, large cerebral arteries divide into pial arteries and
arterioles, which grow gradually deeper and form the penetrating
arteries and arterioles that become progressively smaller until
they turn into cerebral capillaries (Wittko-Schneider et al.,
2014). The development of nerves and astrocytes originating
from central and peripheral sources is closely associated with
cerebral arteries, arterioles, and capillaries as demonstrated
by the observation that the inhibition of angiogenesis during
development is accompanied by severe developmental defects in
specific regions of the central nervous system (CNS) (Hallene
et al., 2006). This highlights the importance of blood vessels
during brain formation.
There are different steps and mediators underlying
neurovascular coupling. Briefly, neurons and interneurons
are responsible for the initiation and modulation of the vascular
response by the activation of NMDA and AMPA receptors,
which leads to an increase of intracellular Ca2+ and calcium-
dependent enzymes that exert effects on the endothelium,
astrocytes, and pericytes. Because of their close association
with synapses and microvessels, astrocytes are in charge of the
neurovascular transmission of signals to the capillaries and
arterioles while endothelial cells exert a retrograde propagation
of vasomotor responses to regulate cerebral blood flow (Iadecola,
2017). The endothelium also regulates the vascular tone by
releasing potent relaxing and contracting factors that readjust
the vascular musculature and maintain a healthy homeostasis of
the vascular wall.
Nitric oxide (NO), prostacyclins, endothelial-derived
hyperpolarizing factor (EDHF), and endothelin have been
proposed as the main vasoactive factors related to the endothelial
response to neural activity. NO promotes the vasodilation of
cerebral blood vessels by stimulating soluble guanylate cyclase
in the vascular muscle, leading to an intracellular increase
of cGMP and relaxation (Schmidt and Walter, 1994). NO
is generated by three different isoforms of the enzyme NO
synthase (NOS): neuronal (nNOS), inducible (iNOS), and
endothelial NOS (eNOS).
In the CNS, nNOS is mainly located in neurons, astrocytes,
and neuronal stem cells and has been implicated in synaptic
plasticity and in the central control of blood pressure.
Abnormal NO signaling is likely to contribute to a variety of
neurodegenerative pathologies such as excitotoxicity following
stroke, multiple sclerosis (MS), Alzheimer’s disease (AD), and
Parkinson’s disease (PD) (Calabrese et al., 2007).
iNOS expression had initially been shown for macrophages,
but it is now clear that it can be induced by cytokines in a variety
of cell types in the context of inflammation (Li et al., 1991).
During episodes of acute inflammation, the role of NO appears
to be protective, while chronic iNOS expression is detrimental.
The high levels of NO produced by activated macrophages and
other cells may not only be toxic to microbes, parasites, or tumor
cells, but may also harm healthy cells (Wong and Billiar, 1995).
Endothelial NOS is mostly expressed in endothelial cells,
although the isozyme has been detected in certain neurons of the
brain (Caviedes et al., 2017). eNOS-derived NO is a well-known
physiological vasodilator and an inhibitor of platelet aggregation
and adhesion, but it also inhibits leukocyte adhesion and vascular
inflammation, controls vascular smooth muscle proliferation,
stimulates angiogenesis, and activates endothelial progenitor cells
(Forstermann and Sessa, 2012).
In addition to the production and release of NO,
cyclooxygenase produces prostacyclin, which induces the
relaxation of cerebral vessels by the activation of adenylate cyclase
with the accumulation of cAMP and the activation of potassium
channels. Similarly, in large cerebral arteries, the production of
EDHF by the cytochrome P-450 monooxygenase metabolism
of arachidonic acid causes relaxation by hyperpolarizing
the underlying vascular muscle through the activation of
potassium channels. The contribution of EDHF increases
as the vessel size decreases, with a predominance of EDHF
activity in resistance vessels and a compensatory upregulation
of hyperpolarization in states characterized by reduced NO
availability (Ozkor and Quyyumi, 2011).
Besides vasodilatory factors, under certain conditions, the
cerebral endothelium produces vasoconstrictive substances such
as endothelins leading to a potent and long-lasting contraction
of cerebral vessels dependent on extracellular calcium and the
activation of protein kinase C (Faraci and Heistad, 1998).
The alterations of any of the cellular players involved in
the neurovascular unit may impair its coupling and functional
hyperemia, resulting in an alteration of homeostasis leading to
brain dysfunction (Iadecola, 2004).
Heart and Vascular Diseases and the
Origin of Neurodegeneration
According to the World Health Organization, cardiovascular
diseases (CVDs) lead to one-third of all annual deaths globally,
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which is about 17.9 million total deaths (Lim et al., 2012).
CVDs are disorders of the heart and blood vessels and include
among others coronary heart disease, cerebrovascular disease,
and rheumatic heart disease. A large number of studies have
reported a strong relationship between indices of vascular
pathology (such as carotid intima-media thickness, arterial
stiffness, and small-artery remodeling) and cognitive impairment
and neurodegeneration (Gorelick et al., 2011).
Because the factors contributing to vascular pathology are
often preventable or treatable, targeting them may prove useful
for preventing or delaying the onset of neurodegenerative
diseases. Epidemiological studies show that treating hypertension
and hyperlipidemia reduces the incidence of neurodegenerative
diseases (Larsson and Markus, 2018) and slows down the rate
of cognitive impairment (Deschaintre et al., 2009). Here, we
will focus on the main CVDs known to promote changes in
the cerebral microvasculature that lead to neurodegeneration
in the long run.
Hypertension
Hypertension – or blood pressure at or beyond 130 mmHg/80
mmHg (systolic/diastolic blood pressure) according to the 2017
American College of Cardiology/American Heart Association
guidelines (Whelton et al., 2018) – affects one billion people
worldwide and leads to nine million deaths every year (Lim
et al., 2012). In normotensive individuals, cerebrovascular
autoregulation counteracts the cerebrovascular effects of the
fluctuations in arterial pressure that occur during normal
activities. Cerebral arteries relax when arterial pressure decreases
and constrict when arterial pressure rises. The role of this vascular
adjustment is the maintenance of a stable cerebral perfusion
despite changes in systemic arterial pressure.
Hypertension alters cerebrovascular autoregulation
(Sadoshima et al., 1983) by impairing endothelium-dependent
relaxation (Faraci and Heistad, 1998). Hypertension promotes
vascular hypertrophy, remodeling, and atherosclerosis in large
cerebral arteries and lipohyalinosis in penetrating arterioles.
These changes are damaging because they reduce the lumen of
the vessel and increase vascular resistance (Dickinson, 2001). In
humans, longstanding hypertension induces the deposition of
collagen and fibronectin as well as elastin fragmentation, leading
to an increased stiffness of the wall of large arteries (Henskens
et al., 2008). Hypertension also affects neurovascular coupling as
shown by a reduction in the normal increase in cerebral blood
flow elicited in the posterior parietal and thalamic areas during
cognitive tasks in patients with chronic untreated hypertension
relative to normotensive individuals (Jennings et al., 2005).
The disruption of the adjustment mechanisms by a sustained
increase in the blood pressure has been linked to different
neurodegenerative diseases such as stroke (MacMahon et al.,
1990). Hypertension is also considered an important modifiable
risk factor for late-life cognitive decline and non-amnestic mild
cognitive impairment in the mid-aged population (Knopman
et al., 2001; Reitz et al., 2007). The Honolulu Asia aging
study demonstrated an association between elevated levels
of blood pressure in middle age and vascular dementia
(Launer et al., 2000).
Atherosclerosis
Atherosclerosis, a progressive disease, characterized by
the accumulation of lipids and fibrous elements in the
large arteries, is a major cause of heart disease and stroke
(Banerjee and Chimowitz, 2017).
The damage leading to atherosclerosis is elicited over years
and is highly influenced by lifestyle. The pathogenic sequence
starts with the recruitment of circulating monocytes into the
intima, where they differentiate into macrophages and internalize
modified lipoproteins to become foam cells (fat-laden M2
macrophages). Then, chemokines and growth factors induce
the proliferation of neighboring smooth muscle cells and the
synthesis of extracellular matrix components within the intimal
compartment, generating a fibromuscular plaque that undergoes
progressive structural remodeling resulting in the formation of
a fibrous cap, overlying a lipid-rich, necrotic core accompanied
by varying degrees of matrix remodeling and calcification (Lusis,
2000). If a rupture of the plaque occurs, the highly thrombogenic
contents of the necrotic core are released to the lumen of the
vessel, promoting atherothrombotic occlusion.
Epidemiological and post-mortem studies have shown that the
atherosclerosis of the arteries that supply the brain is associated
with a two- to threefold increased odds of dementia (Hofman
et al., 1997; van Oijen et al., 2007; Wendell et al., 2012; Dearborn
et al., 2017). Interestingly, this association is independent of the
effects of cerebral infarction (Dolan et al., 2010), which can result
from the atherosclerosis-induced occlusion of vessels.
Cerebral Small-Vessel Disease
Cerebral small-vessel disease comprises white matter lesions
(WMLs), lacunar infarcts, and cerebral microbleeds and is a
frequent neuroimaging finding (best seen on magnetic resonance
images) in elderly people (de Leeuw et al., 2001).
Factors such as arterial stiffness, also related to aging and
hypertension, are considered to expose the small vessels in the
brain to highly pulsatile pressure and flow (Poels et al., 2012).
This causes thickening of the arterial media of these vessels,
which gradually narrows the lumen. In addition, atheroscletoric
plaques in large arteries can encroach on the origins of smaller
arteries, blocking the blood flow to areas supplied by these
arteries. Subcortical white matter is particularly susceptible to
such changes, as its blood supply depends on small arteries that
get progressively smaller as they descend from the cortex to
the deeper parts of the brain. Hypoxia ensues, causing edema,
demyelination, and infarction of the white matter.
Cerebral small-vessel disease is associated with an increased
risk of cognitive decline, dementia, stroke, balance disturbances,
and parkinsonism (Bohnen and Albin, 2011). Individuals with
an identical WML pattern present clinically heterogeneous
complaints in cognitive and motor performance, ranging from
no complaints to dementia and parkinsonism, which means
other factors determine the cognitive or motor outcome (de
Leeuw et al., 2001). Possible explanations for this heterogeneity
are the lack of sensitivity of conventional magnetic resonance
imaging to the early loss of microstructural integrity in the
normal-appearing white matter (Scheltens et al., 1995), the
disagreement on how lesions underlying small-vessel disease
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are classified (Wardlaw et al., 2013), and the efficiency of
compensation mechanisms that prevent further cognitive and
motor deterioration (Mondadori et al., 2006).
Atrial Fibrillation
Atrial fibrillation (AF) is the most common arrhythmia affecting
1 to 2% of the general population (Andrade et al., 2014).
AF is characterized by disturbances that promote ectopic
firing and reentrant mechanisms that lead to impaired atrial
function [for a review on the pathophysiology of AF, refer to
(Andrade et al., 2014)].
AF can lead to reduced cardiac output, intermittent cerebral
hypoperfusion, and transient hypertension in the cerebral
capillaries (Anselmino et al., 2016). Such changes have been
suggested as possible mediators of AF-related brain damage. On
the other hand, AF may be a manifestation of a broader systemic
illness that involves widespread inflammation and platelet
activation, which can also lead to impaired cerebrovascular
function (Dietzel et al., 2018).
AF is associated with increased morbidity and mortality
and has long been known as one of the main risk factors for
embolic stroke (Kamel et al., 2016). It is now also considered
a risk factor for dementia. de Bruijn et al. (2015) analyzed
the association of prevalent and incident AF with incident
dementia in 6514 dementia-free patients, revealing not only
a positive association between AF and the development of
dementia but also that the association was strongest for younger
participants with the longest duration of AF. These findings
have been replicated by several studies (Nishtala et al., 2018),
some of which have shown that the association between AF
and dementia is independent of the occurrence of embolic
stroke (Ryden et al., 2019) and the use of anticoagulants
(Graves et al., 2017). Future investigation will determine if




The link between vascular risk factors and neurodegenerative
disease is strengthened by the evidence showing that vascular
and neurodegenerative pathophysiological changes often co-
exist in patients with a diverse spectrum of neurodegenerative
diseases. Several lines of evidence even suggest that vascular
mechanisms are directly involved in the pathophysiology of
neurodegenerative diseases.
The event that triggers the onset of a stroke, such as
the rupture of an atherosclerotic plaque, the embolization
of a blood clot, or the damage to a vessel and subsequent
bleeding, is often preceded by vascular pathophysiological
changes that accumulate over time. One of the earliest changes
is endothelial dysfunction induced by oxidative stress (Roquer
et al., 2009), which occurs as a result of the aforementioned
cerebrovascular risk factors. Immediately after the onset of
stroke, a series of overlapping pathophysiological changes
occur leading to neuronal death within and beyond the initial
area of damage. These include critically low blood flow, the
accumulation of free oxygen radicals, the sustained or spreading
depolarization of neurons, acidosis, tissue inflammation, damage
to the blood–brain barrier (BBB), and regulated cell death
(Mergenthaler et al., 2004).
The same vascular mechanisms that lead to acute stroke can
also lead to cognitive impairment (Popa-Wagner et al., 2010). In
the condition known as vascular dementia (or vascular cognitive
impairment), the consequences of these pathophysiological
changes are the primary cause of neurodegeneration. They
include the development of multiple or strategically located
infarcts, damage to the myelin sheath and axons, small cerebral
hemorrhages, chronic cerebral hypoperfusion, and brain atrophy
(Iadecola, 2013). Each of these represents damaged tissue, and
the accumulation of damage eventually manifests as cognitive
impairment (Gorelick et al., 2011).
Vascular pathology leading to white matter damage,
manifesting as WML, seems to play a particularly important
role in the pathogenesis of vascular dementia (Iadecola, 2013).
Very often, however, both vascular and neurodegenerative
changes contribute to the development of dementia, resulting in
a condition known as “mixed” dementia.
The link between vascular pathology and neurodegeneration
has also been thoroughly studied in AD. Vascular damage,
initiated by vascular and genetic predisposing factors, precedes
the accumulation of beta-amyloid (Aβ), which eventually
leads to neurodegeneration in AD (Nelson et al., 2016).
Neuroimaging studies support this theory, showing that reduced
CBF and abnormal neurovascular coupling occurs in elderly
people at the risk of AD before they show the hallmarks of
the disease such as brain atrophy, cognitive impairment, or
accumulation of Aβ (Smith et al., 1999; Bookheimer et al., 2000;
Ruitenberg et al., 2005).
Vascular damage may facilitate neurodegeneration by altering
a major route through which substances are cleared from the
interstitial space of the brain parenchyma. This route is known
as the glymphatic system, which facilitates the movement of
fluid from perivascular (Virchow-Robin) spaces surrounding
pial arterioles to the interstitium into spaces surrounding the
brain’s deep veins and then to the cervical lymph nodes
(Jessen et al., 2015).
Vascular risk factors cause blockages in and around small
arteries, which can manifest as an enlargement of the perivascular
spaces (Gouw et al., 2011) that are visible on structural magnetic
resonance images (Wardlaw et al., 2013). These enlarged spaces
are a sign of impeded interstitial fluid flow and hence impaired
clearance of substances from the brain parenchyma, and have
been linked to an increased risk of dementia (Buerge et al.,
2011; Ramirez et al., 2015) and stroke (Mills et al., 2007;
Selvarajah et al., 2009).
Interestingly, the spatial distribution of these enlarged
perivascular spaces has been linked to different underlying
pathologies. A predominant distribution in the basal ganglia
indicates vascular disease caused by hypertension (Selvarajah
et al., 2009; Charidimou et al., 2013), while a white matter
distribution is related to cerebral amyloid angiopathy (Martinez-
Ramirez et al., 2013; Charidimou et al., 2014), caused by the
accumulation of Aβ protein in the walls of the cerebral and
meningeal vessels.
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Cerebral amyloid angiopathy, which leads to intracerebral
hemorrhage that aggravates the cognitive impairment
(Cordonnier, 2011), is found in more than 80% of AD
patients (Jellinger, 2010). Aβ itself is a potent vasoconstrictor
(Thomas et al., 1996), worsening the hypoperfusion, which,
if severe enough, directly injures neurons. However, even
milder hypoperfusion alters protein synthesis and plays a role
in neurodegeneration (Iadecola, 2004). The critical role of
hypoperfusion is supported by the evidence that the induction of
chronic global hypoperfusion in animal models causes memory
impairment, the accumulation of Aβ, and synaptic dysfunction
(Walsh et al., 2002; Koike et al., 2010; Wang et al., 2010).
Blood–brain barrier dysfunction, which involves damage to
pericytes and endothelial tight junction molecules, has been
observed in several neurodegenerative diseases, including AD,
PD, amyotrophic lateral sclerosis (ALS), and Huntington’s disease
(Zlokovic, 2008; Chao et al., 2009; Duran-Vilaregut et al.,
2009; Henkel et al., 2009; Kalaria, 2010; Alvarez et al., 2011).
Vascular damage worsens the situation, both by leading to
further BBB dysfunction and because low blood flow traps
potentially neurotoxic proteins such as Aβ that pass through the
leaky barrier. These proteins, which include immunoglobulins,
plasmin, thrombin, and albumin, further reduce blood flow
and cause vasogenic brain edema, oxidative stress, and axonal
demyelination (Chen and Strickland, 1997; Mhatre et al., 2004;
Farrall and Wardlaw, 2009; Chen et al., 2010). In patients,
this BBB dysfunction is detectable using neuroimaging and the
analysis of the biomarkers of neurodegenerative diseases in the
cerebrospinal fluid (Olsson et al., 2016; Sweeney et al., 2018).
The presence and severity of vascular damage occurring
at the cellular and molecular level, affect the clinical course
of neurodegenerative diseases. Large neuropathological
studies show the post-mortem presence of infarcts, lacunes,
leukoencephalopathy, atherosclerosis, or hemorrhages in 80% of
AD patients compared to 67% of similarly aged people without
cognitive impairment (Toledo et al., 2013).
Interestingly, the effects of vascular pathology and
neurodegeneration on cognitive decline seem to be synergistic,
particularly in patients with moderate AD pathology (Zekry
et al., 2002; Choi et al., 2011; Lee et al., 2014). Studies show that
the worse the vascular pathology in patients with AD, the worse
the cognitive impairment (Snowdon et al., 1997; Song et al., 2007;
White, 2009). AD patients with infarcts or microangiopathic
white matter disease also experience faster cognitive decline
(Silvestrini et al., 2006; Helzner et al., 2009).
CELLULAR SENESCENCE AS THE
ORIGIN OF NEURODEGENERATION
Since a main feature of aging is the accumulation of senescent
cells in various tissues (van Deursen, 2014; Calcinotto et al.,
2019), cellular senescence has emerged as a key potential
contributor to neurodegenerative and cerebrovascular diseases
(Baker and Petersen, 2018; Kritsilis et al., 2018).
Cellular senescence is a phenotype characterized by a
durable cell cycle withdrawal (i.e., cells do not respond to
mitogens), associated with the expression of tumor suppressors
p21CIP1/WAF1 (encoded by Cdkn1a) and/or p16INK4A (encoded
by Cdkn2a), as well as by apoptosis resistance (Figure 1).
Senescent cells display a flattened and vacuolated morphology
with abundant stress granules and accumulate lipofuscin. There
is a persistent DNA damage response commonly detected by
the presence of γH2AX foci, while the most common feature is
an increase in the lysosomal activity of the enzyme senescence-
associated beta galactosidase isoform (SA-B-Gal), which has
been widely used for their detection. Some senescent cells
exhibit a formation of senescence-associated heterochromatin
FIGURE 1 | Senescence-mediated neurodegeneration. Cellular senescence can be induced by several stimuli in the different brain cells. Senescence of microglia
and astrocytes results in inflammation and the loss of trophic support. Oligodendrocyte senescence reduces myelin, which affects transmission and the BBB may be
compromised by endothelial cells senescence. These changes have an impact on the integrity and viability of neurons and ultimately brain function [based on Chinta
et al. (2015)]. SASP, senescence-associated secretory phenotype.
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foci (SAHF), which are domains enriched in the transcription-
silencing histone H2A variant, macroH2A.
However, the most important feature of senescent cells is
the secretion of pro-inflammatory cytokines, growth factors,
extracellular enzymes, and metalloproteases, collectively
known as senescence-associated secretory phenotype (SASP)
(Chow and Herrup, 2015; Ask et al., 2018). In early stages,
the secretion of cytokines by senescent cells promotes the
migration and infiltration of effector immune cells and the
secretion of growth factors and proteases, which facilitate
tissue repair and remodeling (Munoz-Espin and Serrano, 2014;
Davaapil et al., 2017).
Yet, persisting cytokine signaling, as occurs in aging,
contributes among other processes to chronic inflammation
(inflammaging), a major contributor to age-related dysfunctions.
SASP molecules also have an autocrine role, fostering the
senescent phenotype, and a paracrine role inducing senescence
in surrounding cells (Coppe et al., 2010). Notably, during
aging, senescent cells accumulate and persist in different organs,
including the brain, and are associated with the onset of several
diseases (Munoz-Espin and Serrano, 2014).
To avoid confusion, it is however important to differentiate
between aging, often termed “senescence” and cellular
senescence. Aging is featured by an accumulation of senescent
cells, but not all aged cells have the unique cellular senescence
phenotype. Further investigations are needed to understand
why senescent cells accumulate with aging, perhaps involving a
combination of immune system malfunction failing to eliminate
them, with changes in senescent cells themselves so that they
become less efficiently recognized.
Senescence in Neurodegenerative
Diseases
More recent in vitro and in vivo evidence strengthens
the hypothesis of cellular senescence as causative of
neurodegeneration. Dysfunctional astrocytes with senescent
hallmarks have been detected in post-mortem human brain
tissue from patients with ALS, PD, and AD (Bhat et al., 2012;
Chinta et al., 2015, 2018; Turnquist et al., 2016). Mouse
models and in vitro studies provide further evidence of
senescence in microglia (Bussian et al., 2018), endothelial
cells (Broadwell, 1989), neural stem cells and possibly
oligodendrocytes (Kritsilis et al., 2018), which may contribute to
neurodegenerative disorders.
Moreover, several senescent features have recently
been described in studies of both physiological aging and
neurodegenerative diseases using different models, including
AD, PD, MS, and stroke (Kritsilis et al., 2018; Walton and
Andersen, 2019), supporting the idea that cellular senescence
may contribute to neurodegeneration and cerebrovascular
disease in a far-reaching way (reviewed by Baker and Petersen,
2018; Walton and Andersen, 2019).
In a recent publication, using weighted gene co-expression
analysis, Mukherjee et al. (2019) found a microglial signature
of 17 genes that are strongly related with both aging and
neurodegenerative diseases, not only in human brains but also
in neurodegenerative murine models. An early study from Bhat
et al. (2012) suggested that p16INK4A-positive astrocytes may
increase the risk for sporadic AD, since the prefrontal cortex of
AD patients harbors a significant increase of senescent astrocytes
expressing p16INK4a and matrix metalloproteinase-1 (MMP-1).
Also, the in vitro exposure of astrocytes to Aβ1−42 triggers
senescence, leading to the secretion of pro-inflammatory
cytokines, including interleukin 6 (Bhat et al., 2012). Chinta and
colleagues also demonstrated an increase of senescent astrocytes
in brain tissue from PD patients, and found that cultured
murine and human astrocytes exposed to paraquat (an herbicide
associated with sporadic PD) become senescent. Interestingly,
the depletion of senescent cells diminished neurodegeneration
(Chinta et al., 2018), suggesting that senescence may be the cause,
not the consequence of neurodegeneration.
Cellular senescence has also been considered as a therapeutic
target in MS (Oost et al., 2018). Although MS is regarded as a
classical autoimmune disease, it has been hypothesized that the
driver of the autoreactive immune response in MS is actually
a primary neurodegenerative process (Trapp and Nave, 2008).
The senescence of microglia, T-cells, astrocytes, endothelial cells,
and oligodendrocytes, among other cell types, is implicated
in MS pathophysiology (Oost et al., 2018). Even though no
study has been conducted for senescent cell detection on post-
mortem tissue of MS patients, there is initial evidence in animal
models about the role of cellular senescence on MS progression
(Oost et al., 2018).
Senescence and Synaptic Plasticity
Another common hallmark of neurodegenerative pathologies is
the alteration in synaptic structure and function during the early
stages of the disease, which is related to subcellular reorganization
preceding cell loss. The mechanisms underlying these pathologies
are not fully understood. In fact, a decline in synaptic plasticity
may be linked to the phenomenon of senescence. Unfortunately,
there are only a few studies that have investigated the effect
of senescence on the synaptic machinery. However, there is
growing evidence of the changes in neuroplasticity caused by
inflammation, oxidative stress, and protein misfolding, that may
be linked to SASP action as well as the influence of senescence
in glial cells, which are associated with an impairment in the
neuroplasticity machinery (Gan et al., 2018).
The hippocampus has been pointed out as a brain structure
with high plasticity and prone to neurodegeneration with
age (Kreutzmann et al., 2015). The neurogenic capacity of
the hippocampal dentate gyrus is reduced during aging. This
reduction correlates with an impairment in memory formation
and is accompanied by other changes, such as an increase
of pro-inflammatory cytokines as well as a reduction of
neurotrophic and vascular factors (Seib and Martin-Villalba,
2015; Fan et al., 2017).
Aging is also associated with changes in the hippocampal
perforant pathway and its synapses, with the dentate gyrus being
particularly affected (Wenk and Barnes, 2000). A decrease of
synapses and changes in the morphology of dendrites and their
spines have been linked to atrophy and a dysfunction of the
aged hippocampus (Rogers et al., 1984). A synapto-proteome
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study in old animals revealed a general decrease in the expression
of neurotransmission regulation proteins, such as post-synaptic
density 95, synaptosomal nerve-associated protein 25, shiga
toxin 1, synapsin 1 and 2, synaptophysin, and vesicle-associated
membrane protein (Wang et al., 2007; VanGuilder et al., 2010;
Orock et al., 2019).
Moreover, a recent breakthrough paper, using a classical
model of neurodegeneration, shows the accumulation of
senescent astrocytes and microglia, but not neurons, in the brains
of mice overexpressing human TauP301S. The genetic clearance
of senescent glial cells prevented neurofibrillary tangle (NFT)
deposition, the degeneration of hippocampal neurons, brain
shrinkage, and the thinning of the dentate gyrus, thus preserving
cognitive function. The transgenic mice that did not undergo
a senescent transformation of microglia cells maintained their
cognitive functions (Bussian et al., 2018).
Interestingly, neurogenesis and learning and memory can
be impaired when blood and plasma from aged animals are
transfused to young animals, showing that systemic factors
can affect brain integrity. This phenomenon may be related
to chemokine levels, especially the C–C Motif Chemokine
Ligand 2 (CCL2), an important SASP component (Villeda et al.,
2011). It is possible that when senescent astrocytes accumulate,
they release SASP factors that lead to NFT deposition and
other neurodegenerative hallmarks in surrounding neurons,
oligodendrocytes, microglia, and endothelial cells (Figure 1).
Investigating senescent cell accumulation in the periphery and
in the nervous system should help to understand the process of
aging of the brain and, more importantly, neurodegeneration in
an integrative way.
Cellular Senescence in Stroke
Cellular senescence accompanying neurological conditions
involves many cell types of the CNS (Walton and Andersen,
2019), which may also be of great importance in the case of
brain injury following stroke (Buga et al., 2013). Most studies
in this field, however, focused on the effects of aging rather
than on cellular senescence. The timing of the cellular and
genetic response to brain tissue injury is dysregulated in aged
animal models due to a premature accumulation of BrdU-
positive microglia and astrocytes, activated oligodendrocytes, and
degenerated neurons (Popa-Wagner et al., 2007).
There is no consensus whether and to what extent age
influences infarct size: several studies reported larger (Popa-
Wagner et al., 2011) or smaller ischemic lesions in aged animals
when compared to young rodents (Manwani et al., 2013; Ritzel
et al., 2018). However, irrespective of the infarct size, aged animals
have worse functional when compared to young ones (Popa-
Wagner et al., 2011; Ritzel et al., 2018). The slow tissue recovery
and rapid development of damage after injuries like stroke in
aged animals may be linked to several factors such as a reduced
expression of genes linked to neuroprotective pathways, high
and accelerated cell death, high oxidative stress by mitochondrial
dysfunction, increased permeability of the BBB, high phagocytic
activity of brain macrophages, autophagic dysfunction, as well
as an imbalanced inflammatory state (Popa-Wagner et al., 2007,
2011; Petcu et al., 2008).
Furthermore, the immune response to ischemic brain injury
differs between aged and young mice. In a recent report,
older mice displayed an increased number of brain-infiltrating
and peripheral neutrophils with decreased phagocytic potential,
increased levels of reactive oxygen species and extracellular
matrix-degrading enzymes (Ritzel et al., 2018). Rawji and
colleagues reported that aging also affects brain-resident immune
cells. Aged microglia express excessive amounts of pro-
inflammatory cytokines and proliferate at increased rates, but
simultaneously display defective phagocytosis and decreased
motility. Interestingly, aged peripheral monocytes seem to share
the features of impaired phagocytosis and reduced motility, but
are less prone to activation and proliferation (Rawji et al., 2016).
Since aging has been linked to the accumulation of senescent
cells (van Deursen, 2014; Calcinotto et al., 2019), we speculate
that cellular senescence may contribute to the outcome after
stroke. However, there is a need for more studies, exploring
specifically the impact of cellular senescence rather than the
global effects of aging. In vitro and in vivo experiments show
that aging influences the state of endothelial cells, pericytes, and
tight junctions, in turn resulting in a compromised function
of the BBB (Yamazaki et al., 2016). Acute stroke leads to
increased permeability and BBB breakdown, associated with
worse outcome in stroke patients (Brouns et al., 2011).
Astrocytes in aged brains display the features of cellular
senescence and SASP (Salminen et al., 2011), possibly impacting
surrounding cells also in the case of acute brain damage. In the
context of senescence hallmarks, human astrocytes are highly
sensitive to oxidative stress and trigger a senescence program
when faced with multiple types of stressors (Crowe et al., 2016;
Liddell, 2017).
Chronic low-grade inflammation contributes to the increased
risk of cerebrovascular disease (Lucas et al., 2006) and was shown
to be a feature of the aging (Buga et al., 2013). The SASP in many
cell types, including peripheral immune cells, astrocytes and
microglia may influence a chronic inflammatory state observed
in aging (Buga et al., 2013).
Taking into consideration the pathogenesis of cerebrovascular
diseases, it is important to mention that cellular senescence
may play a role in comorbidities and conditions known as risk
factors for stroke (Buga et al., 2013). Cellular senescence impacts
the formation and state of atherosclerotic plaques (Ritzel et al.,
2018) and endothelial cells showing the hallmarks of senescence
triggered by stressors like changes in glucose levels, homocysteine
or elevated blood pressure (Tian and Li, 2014) may play a role
in age-related vascular diseases. Since cellular stress induces
senescence, it remains to be experimentally tested whether stroke
itself triggers senescence in brain cells, which may influence the
CNS microenvironment, have long-term consequences and an
impact on the outcome after cerebral insults.
Systemic Metabolic Disease, Cellular
Senescence, and Neurodegeneration
Risk factors in many neurodegenerative disorders include
systemic metabolic diseases (see section “Impact of Peripheral
Metabolic Disorders on Neurodegeneration”), which, in fact,
favor the accumulation of senescent cells by facilitating the
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functional changes of cellular distribution and regulation of
adipose tissue. As mentioned before, cellular senescence in aging
may contribute to a chronic inflammatory state in the brain and
peripheral tissues (Buga et al., 2013).
Interestingly, obesity generates an accelerated state of aging,
pro-oxidant factors as well as glucotoxicity (Hardie et al., 2006;
Eberle and Ament, 2012). It is also associated with an increased
senescent cell burden and a wide range of neurodegenerative and
neuropsychiatric diseases (Gariepy et al., 2011; Hryhorczuk et al.,
2013; Morsi et al., 2018). Ogrodnik and colleagues demonstrated
that, in obese mice, glial cells show increased markers of
cellular senescence in the periventricular region of the lateral
ventricle, a region in close proximity to the neurogenic niche
(Ogrodnik et al., 2019).
Furthermore, the affected glial cells in obese mice display
excessive fat accumulation, which is in agreement with the
role of glial cells on the senescence-mediated induction of
neurodegeneration. Since SASP contributes to inflammation,
metabolic dysregulation, progeria, pulmonary fibrosis, geriatric
syndromes, and the loss of resilience, the clearance of senescent
cells may delay or even alleviate multiple age-related diseases
(Kirkland and Tchkonia, 2017).
Taking into consideration the increasing body of evidence
on the role of cellular senescence in neurodegenerative,
cerebrovascular, and metabolic disorders, we propose to
investigate senescent cell accumulation in the periphery and in
the nervous system as well as the influence of SASP on processes
in the CNS, such as neuroplasticity, specific cellular populations,
and on the brain–body signaling. This will help to understand
the normal process of aging and senescence in an integrative way.
BODY–BRAIN TROPHIC INTERACTIONS
AS THE ORIGIN OF
NEURODEGENERATION
The disruption of the bidirectional interaction between neurons
and the cells they innervate has not been considered as a putative
etiologic mechanism of neurodegeneration. According to the
trophic theory of neural connections, the body is represented
several times within the nervous system along the sensory and
motor pathways (Purves, 1988). Thus, changes in size and
function of the body must be accompanied by changes in their
neural representation at a central level, which may include neurite
remodeling and functional adaptations.
Furthermore, novel requirements of the body affect the
peripheral and central connections of peripheral neurons. In
early phases of metabolic disorders, adipocytes and immune cells
are related to peripheral nerve remodeling of both sympathetic
and sensory fibers (Pellegrinelli et al., 2018; Yamazaki et al., 2018).
In addition, the alteration of the enteric nervous system (ENS)
may be a conduit to induce changes in the CNS. Future studies
oriented to understand the interactions between neurons and
the cells they innervate would help to discover biomarkers for
early diagnosis and to monitor disease progression. Here, we
present a brief summary of the experimental evidence related to
the early events of neurodegeneration in the body and discuss
possible mechanisms of intercellular communication that may be
operating (Figure 2).
Pathological Events in the Peripheral
Nervous System
Various neurodegenerative diseases share common molecular
and cellular mechanisms including the misfolding of proteins
that undergo conformational changes leading to tissue deposition
and the formation of inclusion bodies. Increasing evidence
suggests that these neurodegenerative proteinopathies may
originate in the peripheral nervous system (Wakabayashi et al.,
2010) or even across the body.
In PD and dementia with Lewy bodies (DLBs), the
histopathological hallmark is the occurrence of neuronal
α-synuclein aggregates, also known as Lewy bodies. Lewy bodies
are typically found in the substantia nigra in PD. However,
LBs can also be present in peripheral organs, neural or not,
including the sympathetic ganglia, ENS, cardiac and pelvic
plexuses, submandibular gland, adrenal medulla, and the skin
(Beach et al., 2010; Wakabayashi et al., 2010). Moreover, in
the early pathological stages of PD, α-synuclein pathology is
present first in the dorsal motor nucleus of the glossopharyngeal
and vagal nerves as well as the anterior olfactory nucleus
(Braak et al., 2003a).
In AD, NFTs are observed in the spinal and sympathetic
ganglia. However, it seems that they develop independently of the
cerebral AD pathology (Shankle et al., 1993). In ALS, TDP-43 is a
major component of the ubiquitinated inclusions and also occurs
in the neurons of the spinal ganglia (Nishihira et al., 2008).
Sensory abnormalities have been described in
neurodegenerative diseases including PD and AD. In this
regard, the loss of olfaction represents an important early
clinical symptom frequently preceding motor and cognitive
impairments typically observed in these neurodegenerative
diseases (Driver-Dunckley et al., 2014; Doty, 2017; Marin
et al., 2018; Rey et al., 2018). The olfactory system may be
particularly affected in neurodegenerative diseases as seen by
the accumulation of pathological protein aggregates in olfactory
structures including the anterior olfactory nucleus, the olfactory
bulb, and the olfactory epithelium (OE) (Doty, 2017; Marin et al.,
2018; Rey et al., 2018).
Given that the OE is directly accessible to external factors,
it is vulnerable to environmental insults. Thus, external
agents (toxins, bacteria, viruses, air pollutants) may trigger
neurodegeneration through the OE (Rey et al., 2018). Once
these agents enter the brain via the OE, they may cause protein
misfolding and the spreading of protein aggregates in a prion-like
manner throughout the olfactory pathway to other anatomically
connected brain regions (Doty, 2017).
Moreover, xenobiotics and particles in contact with the OE can
also induce the production of reactive oxygen species triggering
a local inflammatory reaction in a similar way to that induced by
misfolded proteins (Lema Tome et al., 2013). Alternatively, the
enhanced expression of misfolding-prone proteins in olfactory
structures may make those regions prone to develop certain
diseases (Duda et al., 1999; Taguchi et al., 2016; Kim et al., 2018).
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FIGURE 2 | The role of trophic interactions between the brain and the body in the development of neurodegenerative diseases. Under physiologic conditions, there
is a continuous exchange of information between neurons and their targets. Neurons control several aspects of the cells they innervate by the release of
neuropeptides and neurotransmitters. Reciprocally, peripheral cells modulate neuronal physiology by the release of several molecules including neurotrophins and
cytokines. Recently, extracellular vesicles (EVs) have been considered as key players in the development and progression of chronic and degenerative diseases. An
alteration of the homeostatic state of peripheral cells is reflected on the molecular cargo of EVs which, in turn, can affect the functioning of the neurons. Common to
several chronic and neurodegenerative diseases, there is a reduction of peripheral innervation which leads to a disturbance of the trophic relation between the body
and the central nervous system. A continuous alteration of these interactions during maturity of individuals may underlie some of the early events that reflect on
neuronal death during aging. CNS, central nervous system; EVs, extracellular vesicles; PNS, peripheral nervous system.
Pain abnormalities are part of the clinical features in patients
with PD and the impaired nociceptive processing depends on
nociceptor degeneration (Nolano et al., 2008; Reichling and
Levine, 2011; Conte et al., 2013). Skin biopsies of PD patients
reveal a decrease in cutaneous autonomic innervation, free
epidermal nerve endings, and encapsulated sensory endings
(Dabby et al., 2006; Nolano et al., 2008). The severity of PD
correlates with the loss of Meissner corpuscles and epidermal
nerve fibers, accompanied by a reduction in cold and pain
perception (Nolano et al., 2008).
The accumulation of misfolded proteins such as α-synuclein
and parkin due to a dysfunction of the ubiquitin-proteasome
system may partially explain the painful nociceptor dysfunction
(Saha et al., 2000). In AD, pain perception seems not to be
reduced. However, more studies are necessary to document
whether sensory innervation is modified in AD and other
neurodegenerative diseases (Cole et al., 2006). Of note, it
is important to mention that different mechanisms involving
both peripheral and central pain pathways may play a role in
sensory dysfunction.
Autonomic dysfunction is present in several
neurodegenerative diseases including PD, multiple system
atrophy, AD, and other types of dementia such as DLB, PD with
dementia, and frontotemporal lobar degeneration (Idiaquez and
Roman, 2011; Coon et al., 2018). Orthostatic hypotension has
been widely reported in patients with PD and DLBs as seen
by the decreased cardiac uptake of the noradrenaline analog
meta-iodobenzylguanidine (Orimo et al., 2005).
The presence of orthostatic hypertension may be due
to the depletion of cardiac vagal sympathetic nerves as
well as the α-synuclein pathology in sympathetic ganglia
and adrenal gland that have been reported in Lewy body
diseases, which includes PD, PD with dementia, and DLB
(Wakabayashi et al., 2010). Interestingly, sympathetic
denervation precedes neuronal loss in the sympathetic
ganglia (Orimo et al., 2005). Autonomic dysfunction in AD
may also be affected by neuropathological changes in central
autonomic networks (Collins et al., 2012). Future studies
should focus on the temporality of autonomic alterations in
neurodegenerative diseases.
Gastrointestinal dysfunction is closely linked to the
dysfunction of the ENS. Enteric dysfunction has been reported in
PD, AD, ALS, and frontotemporal dementia (Rao and Gershon,
2016). Biopsies of PD patients have demonstrated the presence
of Lewy-type pathology in enteric neurons suggesting a role
of the ENS in the onset of the disease (Kupsky et al., 1987;
Wakabayashi et al., 1988, 1990). The unmyelinated axons of
enteric neurons may increase their susceptibility to PD and
due to their multiple synaptic terminals may promote the
propagation of α-synuclein aggregates via connected ganglia
(Chalazonitis and Rao, 2018).
Likewise, in AD patients, Aβ immunoreactivity is found
in the submucosa of the intestine (Joachim et al., 1989). In
addition, amyloid precursor protein expression is present in the
enteric neurons of AD patients (Arai et al., 1991). However,
in contrast to PD, data from human samples in AD are still
sparse. Other autonomic dysfunctions reported include urinary
symptoms, sexual and thermoregulatory, dysfunction, and sleep
disturbances (Postuma et al., 2015; Racosta et al., 2015; Pfeiffer,
2016). A better characterization of peripheral damage is required
Frontiers in Neuroscience | www.frontiersin.org 10 July 2019 | Volume 13 | Article 728
fnins-13-00728 July 22, 2019 Time: 17:18 # 11
Castillo et al. Neurodegeneration Revisited
in those cases where there is evidence of alteration in the
peripheral innervation.
Impact of Peripheral Metabolic Disorders
on Neurodegeneration
An increasing body of evidence suggests that metabolic
disturbances may contribute to neurodegenerative processes in
the CNS. We discuss here briefly the impact of diabetes mellitus
(DM) and obesity on neurodegeneration.
Diabetes mellitus is one of the most common metabolic
diseases and a major disorder of insulin regulation with
increasing incidence (Duarte et al., 2012). Especially
type 2 diabetes (T2D) is a highly complex, multifactorial
metabolic disease, characterized by a progressive pancreatic
β-cell failure (relative insulin deficiency), decreased insulin
action and peripheral insulin resistance (Campbell, 2011;
Carvalho et al., 2012).
T2D develops under a cluster of risk factors that includes
high blood glucose, obesity, increased blood triacylglycerols and
insulin resistance, which individually or collectively, also increase
the risk for neurodegeneration/neuronal death, functional and
structural brain changes, culminating in cognitive dysfunction
that underlies dementia-type disorders (e.g., AD), which may
arise from a complex interplay between T2D and brain aging.
Additionally, decreased brain insulin levels/signaling and glucose
metabolism in both pathologies further suggests that an effective
treatment strategy for one disorder maybe also beneficial in the
other (Duarte et al., 2013).
Obesity is clinically identified based on measurements of body
mass index, but can be generally defined as the condition in which
excess body fat has accumulated to an extent that can negatively
affect health. This definition is based on the dramatically
enhanced risk for a myriad of disorders, including T2D, CVD,
gastrointestinal and respiratory disorders, and several types of
cancer (for review, see Haslam and James, 2005). Furthermore,
abdominal obesity is a component of the metabolic syndrome,
which additionally combines insulin resistance or glucose
intolerance, atherogenic dyslipidemia, elevated blood pressure,
and increased expression of prothrombotic and proinflammatory
markers (for review, see Olufadi and Byrne, 2008) and is an
important risk factor for T2D, CVD, and stroke.
While the consequences of obesity on metabolic and
cardiovascular pathophysiology are well-studied, epidemiological
and experimental data are beginning to reveal that the CNS may
also be detrimentally affected by obesity and obesity-induced
metabolic dysfunction. In particular, data show that obesity is
associated with cognitive decline and enhanced vulnerability
to brain injury, while experimental studies in animal models
confirm a profile of increased susceptibility to brain damage and
decreased cognitive function (Bruce-Keller et al., 2009).
Recent data suggest that both AD and PD can manifest
systemic alterations in energy metabolism (e.g., increased insulin
resistance and dysregulation of glucose metabolism). Moreover
emerging evidence that dietary restriction can forestall the
development of AD and PD is consistent with a major
“metabolic” component to these diseases, and provides optimism
that these devastating brain disorders of aging may be largely
preventable (Blum-Degen et al., 1995; Mattson et al., 1999).
Advanced glycation end products generated by chronic
hyperglycemia and their receptor RAGE provide critical links
between diabetes and AD (Vicente Miranda et al., 2016; Fleitas
et al., 2018). Obesity, diabetes, and metabolic syndrome increase
the risk of cognitive decline and dementia, including not only
vascular dementia, but also AD and PD (Roriz-Filho et al., 2009).
However, due to increased incidence, especially in the
aging population, the impact of metabolic disease on
neurodegenerative processes will increase tremendously in
the upcoming decades. We believe therefore that potential
therapeutic approaches aiming at preventing/treating
neurodegenerative diseases should include metabolic disorders.
Altered Body–Brain Trophic
Communication
Accumulating evidence suggests that patients with
neurodegenerative diseases commonly develop sensory and
autonomic dysfunctions during maturity. This raises the
possibility that the peripheral nervous system may be the
gateway to alter brain physiology. The trophic theory of neural
connections states that there is a mutual dependence between
neurons and their targets (Purves, 1988; Qureshi and Mehler,
2013; Holm et al., 2018). Olfactory or gastrointestinal alterations
may reflect a distortion of the communication between a variety
of cell types and peripheral neurons. The repercussion of these
altered interactions on the development of neurodegenerative
diseases are still underexplored. Moreover, the mechanisms of
cellular communication between peripheral cells and the nervous
system are not fully characterized.
Recently, a novel system of intercellular communication has
been proposed to modulate changes in neuronal physiology and
to participate in the propagation of misfolded proteins (Fevrier
et al., 2004; Asai et al., 2015; Grey et al., 2015; Polanco et al., 2016).
This system is mediated by membranous organelles denominated
as EVs, which can travel from the periphery to the brain and vice
versa (Li et al., 2018).
Apparently, all the cell types of the body can release
EVs to transmit information in the form of proteins, RNAs,
and lipids. EVs are classified according to their subcellular
origin in exosomes when originating from multivesicular bodies
and in ectosomes (or microvesicles) when formed from the
plasma membrane (Thery et al., 2018). Despite the technical
challenges to study the functional role of different EVs
subpopulations, their participation in both the maintenance of
tissue homeostasis and the progression of chronic degenerative
diseases is becoming clearer.
Extracellular vesicles are involved in several processes
of brain development and normal functioning, including
synapse formation, synaptic plasticity, and communication
between glia and neurons. The signaling proteins of
hydrophobic nature, such as the Wnt family members and
other regulatory proteins, are loaded into EVs (Korkut
et al., 2009; Coulter et al., 2018; Lee et al., 2018). During
mammalian brain development, the vesicular secretion of the
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growth factor sonic hedgehog promotes the proliferation of
neural progenitors.
Interestingly, the loss of function of the complex charged
multivesicular body proteins 1A reduces the number of
intraluminal vesicles and the secretion of a specific subtype of
EVs whose functions can be directly related to sonic hedgehog
signaling (Coulter et al., 2018). At the Drosophila neuromuscular
junction, EVs containing the Wnt-binding protein Evennes
Interrupt and the Wnt 1 homolog Wingless promote synaptic
growth when released from the presynaptic terminal (Korkut
et al., 2009; Koles et al., 2012).
There is a constant reciprocal exchange of information
through EVs between the pre- and post-synapse to modulate
fine aspects of synaptic maturation and remodeling. In rat
hippocampal neurons, excitatory synapses can be eliminated by
a mechanism dependent on the delivery of Proline-Rich 7 by
exosomes to induce the degradation of the post-synaptic density
protein-95 (Lee et al., 2018).
Extracellular vesicles contents also influence long-term
memory and synaptic plasticity. In neuronal cultures from mouse
hippocampus and in neuromuscular junction preparations from
Drosophila, oligomers of the activity-regulated cytoskeleton-
associated protein and its own mRNA are transported through
exosomes to the post-synapse (Ashley et al., 2018; Pastuzyn
et al., 2018). The translation of the exosomal activity-
regulated cytoskeleton-associated protein mRNA increases by
the activation of the group 1 metabotropic glutamate receptors
(Pastuzyn et al., 2018). The notion that neurons constantly use
EV-mediated communication is reinforced by the fact that the
release of EVs is activity-dependent and that the delivery of the
cargo from presynaptic cells enables retrograde signaling from
the post-synaptic cells (Lachenal et al., 2011; Korkut et al., 2013;
Lee et al., 2018).
The general hypothesis on the role of EVs related to
the development of neurodegenerative diseases relies on their
potential to transport protein aggregates, which has been
reviewed elsewhere (Howitt and Hill, 2016). Here, we would like
to center the discussion on the possibility that a bidirectional
exchange of information through EVs between peripheral
cells and neurons may have a long-term impact on the
brain physiology.
Emerging evidence suggests that both central and peripheral
neurons can uptake EVs from a variety of cell types. Thus,
under certain circumstances, EVs derived from peripheral cells
contain proteins or RNAs that can be deleterious for neuronal
functioning. In agreement with this notion, exosomes derived
from hyperglycemic Schwann cells contain microRNAs that
suppress axonal growth in vitro (Jia et al., 2018). Moreover,
hyperglycemic Schwann cell-derived exosomes contribute to the
development of diabetic peripheral neuropathy when injected
into a diabetic mouse (Jia et al., 2018).
Similarly, the CNS can also be affected by the information
transported by systemic exosomes. An increase of inflammatory
cytokines in the brain and microglial and astrocytic activation
is observed after the intravenous injection of serum-derived
exosomes from lipopolysaccharide (LPS)-challenged mice
(Balusu et al., 2016; Li et al., 2018). Dorsal root ganglion
neurons modulate immune cells in the periphery by the release
of neuropeptides.
Recent findings also indicate that EV-mediated
communication can be an additional mechanism operating
during trauma. After nerve injury, dorsal root ganglia neuron-
derived exosomes loaded with microRNA-21 increase the
infiltration of inflammatory macrophages, which contributes
to neuronal sensitization (Simeoli et al., 2017). Further work is
required to obtain insights whether EVs from peripheral cells
modulate cellular processes in the brain under physiological
conditions and which factors can alter the messages coming from
the periphery (Ridder et al., 2014).
Despite the few studies focusing on the influence of
peripherally derived EVs on peripheral neurons, it is likely
that peripheral terminals establish a bidirectional interaction
with the cellular elements surrounding them. Both sensory and
autonomic axon terminals usually end as free nerve endings
in the extracellular matrix intercalated between different cell
types. Peripheral neurons are responsive to EVs derived from
mesenchymal stem cells and Schwann cells (Lopez-Verrilli et al.,
2013, 2016; Ching et al., 2018; Sun et al., 2018; Shiue et al., 2019).
The general observation of these studies, performed in conditions
of neuronal damage, is that EVs reduce the inflammatory
state and have a beneficial role in axonal growth both in vivo
and in vitro.
Taken together, these findings indicate that neurons are
susceptible to modify their functioning or gene expression
profile as a result of incorporating EVs from neighboring cells.
A challenge for future studies is to determine if EVs from any
cell source can modify neuronal functioning and how these
events are associated with physiological alterations that precede
neurodegeneration in the brain.
GUT DYSBIOSIS AS THE ORIGIN OF
NEURODEGENERATION
Microbiota is defined as a community of all microorganisms
living in our body. Microbiota therefore includes all
taxonomic domains such as fungi, protozoa, viruses, and
bacteria. Bacterial microbiota living in the gut (further
referred as GM) represent about 90% of all microbiota in
the body (Thursby and Juge, 2017), with an estimated ratio
of human:bacterial cells close to 1:1 (Sender et al., 2016).
This large number of bacteria offers different benefits to
the host, confers protection against pathogens (Baumler
and Sperandio, 2016), regulates host immunity (Gensollen
et al., 2016), and products originating from bacterial
fermentation can be used as a source of energy for colonocytes
(den Besten et al., 2013).
A delicate balance exists between the GM composition
and its interaction with the host, while an imbalance in this
composition is commonly known as dysbiosis. Gut dysbiosis has
been implicated in the development of chronic diseases, such as
irritable bowel syndrome (Raskov et al., 2016), coeliac disease
(Verdu et al., 2015) as well as metabolic disorders, including
obesity, metabolic syndrome, and T2D (Holmes et al., 2011;
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TABLE 1 | Alterations in gut microbiota at PHYLUM level in AD patients and AD transgenic mice.
Model Bacterial phylum INCREASED Bacterial phylum DECREASED References
AD patients Actinobacteria Bacteroidetes Zhuang et al., 2018
AD patients Bacteroidetes Firmicutes Vogt et al., 2017
3×TG-AD mice 8 months old Firmicutes – Sanguinetti et al., 2018
3×Tg-AD mice 24 months old – Tenericutes
Cyanobacteria
Bonfili et al., 2017
APP/PS1 mice 8 months old Firmicutes Bacteroidetes
Proteobacteria
Park et al., 2017
APP/PS1 mice 1 month old Firmicutes Bacteroidetes Harach et al., 2017






Harach et al., 2017
5×FAD mice 9 weeks old Firmicutes Bacteroidetes Brandscheid et al., 2017
Carding et al., 2015; Zhang et al., 2015; Baothman et al., 2016;
Org et al., 2017).
Notably, those metabolic diseases, when developed during
adulthood, are considered important risk factors for AD
(Alzheimer’s Association, 2016; Livingston et al., 2017).
Furthermore, metabolic alterations are known to induce
peripheral low-grade chronic inflammation, associated with
higher incidence of neurodegenerative diseases. In AD, systemic
inflammation during prodromal stages shortens disease onset
(Tao et al., 2018), whereas dysregulation of the gastrointestinal
function and colonic inflammation diminished immune
competence and preceded motor symptoms in PD patients
(Dobbs et al., 1999; Braak et al., 2003b; Lebouvier et al., 2009;
Villaran et al., 2010; Forsyth et al., 2011).
During aging, there is an increased permeability of the gut
epithelium (Tran and Greenwood-Van Meerveld, 2013). This
condition allows bacteria and bacterial products to translocate
through the disrupted gut barrier reaching peripheral organs
(Zevin et al., 2016). Newest reports suggest that translocated
bacteria may even reach the brain (Roberts et al., 2018), where
an exacerbated immune reaction can lead to neurodegeneration.
These observations remain however to be investigated in detail.
Gut Microbiota Alterations in
Neurodegenerative Diseases
Recent reports concomitantly demonstrate a gut dysbiosis in PD
(Minato et al., 2017; Wu et al., 2017), ALS, and AD patients
(Cattaneo et al., 2017; Vogt et al., 2017).
Understanding how GM may be implicated in brain
pathologies requires a clear comparison among the data reported
from different research groups. The GM is mainly dominated
by four phyla: Firmicutes, Bacteroidetes, Actinobacteria, and
Proteobacteria (Szablewski, 2018). The first studies described GM
alterations only at the phylum level. However, recent advances
in sequencing techniques allow distinction at the species level,
which is advantageous since the different species of bacteria
belonging to the same genus affect host physiology in a different
manner. We compared previously published GM data obtained
from AD patients and AD mice models. We noted a strong
variation between studies: at phylum level, most transgenic
models coincide with an increased abundance of Firmicutes but a
decreased abundance of Bacteriodetes (Table 1). Whereas at the
family and upper taxonomical levels (i.e., genus/species), there is
no more consistency (Table 2).
Importantly, variations in the experimental design or the type
of samples can be observed. Moreover, differences in the animal
model, chronological stage of the pathology (age), handling and
diet significantly impact GM (Mueller et al., 2006; Hufeldt et al.,
2010; Sanchez-Tapia et al., 2017). Thus, experimental variations
among published studies may explain discrepancies in the GM
composition in AD.
Despite this strong variation, we can observe a general
increased abundance of pro-inflammatory bacteria in AD mice
and AD patients (Kountouras et al., 2009; Zhan et al., 2016;
Cattaneo et al., 2017; Shen et al., 2017; Vogt et al., 2017;
Zhang et al., 2017; Syeda et al., 2018) compared to controls.
Furthermore, in AD transgenic mice, longitudinal studies clearly
indicate an age-associated gut dysbiosis, culminating in a strong
pro-inflammatory environment along the development of brain
pathological hallmarks (Shen et al., 2017; Zhang et al., 2017;
Syeda et al., 2018).
How Can the GM Affect Brain Function
or Even Cause Neurodegeneration?
A bidirectional communication between the gastrointestinal
system and the brain has been described and has led to the
concept of gut-brain axis (Collins and Bercik, 2013). Recent
studies illustrated the role of GM in brain Aβ aggregation, as
GM absence in germ-free condition (Harach et al., 2017) or
GM partial depletion by antibiotic treatment (Minter et al.,
2016) reduced the amyloid burden and microglia activation in
AD transgenic mice. However, it is still unclear which factors
may be associated with the above described gut-brain axis in
brain pathologies.
Several groups have implicated the neurotoxin LPS present
in the outer membrane of gram-negative bacteria. LPS plays
key roles in the host-pathogen interactions of the innate
immune system (Hill and Lukiw, 2015; Maldonado et al., 2016).
Alterations in the GM composition/abundance are associated
with enhanced plasma levels of LPS (Avila-Nava et al., 2017;
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TABLE 2 | Alterations in gut microbiota in AD patients and AD mice at FAMILY, GENUS, and SPECIES levels.
Model Bacterial family (f.)/genus (g.)/
species (g. s.) INCREASED
Bacterial family (f.)/genus (g.)/
species (g. s.) DECREASED
References
AD patients g. Escherichia/Shigella g.s. Eubacterium rectale Cattaneo et al., 2017
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Sanchez-Tapia et al., 2017), which may result in an exacerbated
metabolic endotoxemia (Cani et al., 2012), a condition
characterized by inflammation and the increased release of
pro-inflammatory cytokines.
Systemic infections have been related to a higher possibility
to develop AD (Holmes et al., 2009) as well as early motor
dysfunction in PD patients (Dobbs et al., 1999). Therefore, long-
term gut microbiota alterations and gut dysbiosis resulting in a
pro-inflammatory environment and inflammation may be linked
to brain dysfunction in aging.
As a proof of concept, LPS is detected in the parenchyma
and blood vessels of both, non-demented aged and AD brain
samples, but at a higher level in diseased tissues (Zhao et al.,
2015, 2017; Zhan et al., 2016). LPS also increases in the plasma
of AD transgenic mice compared to wild type controls (Syeda
et al., 2018). In PD patients, higher plasma LPS correlates with
α-synuclein aggregation (Forsyth et al., 2011). Furthermore, LPS
is a well-known neuroinflammatory agent driving the generation
of Aβ1−42 (Lee et al., 2008; Asti and Gioglio, 2014; Hill and Lukiw,
2015; Zhao et al., 2015). LPS administration to mice results in
memory impairment, Aβ aggregation, and astrocyte activation
(Lee et al., 2008). Therefore, gut dysbiosis may enhance LPS
to the blood circulation and even to the brain, producing glia
activation and protein aggregation, both important features of
neurodegenerative diseases.
Another bacterial product related to the development of
neurodegenerative diseases are short-chain fatty acids (SCFAs).
SCFAs are produced by the GM after the degradation of
non-digestible polysaccharides, with butyrate, acetate, and
propionate being the more abundant fermentation products
(Wong et al., 2006). About 95% of the SCFAs produced
in the gut are absorbed within the colon (Hoyles et al.,
2018), while butyrate is used by the colonocytes as an
energy source. In order to maintain an optimal equilibrium
between intestinal SCFAs and the concentration in the body,
the gut intestinal barrier increases its mucus production
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(Rios-Covian et al., 2016), while the liver clears the majority of
propionate and butyrate from the portal circulation (Bloemen
et al., 2010). However, SCFAs can be transported through the
bloodstream to reach the brain.
Some alterations in fecal SCFAs concentration have been
described in AD transgenic mice compared to controls (Bonfili
et al., 2017; Zhang et al., 2017). Butyrate, a well-known
neuroprotective agent (Minamiyama et al., 2004; Govindarajan
et al., 2011; Liu et al., 2015), is reduced in the fecal samples
of AD mice (Zhang et al., 2017). Other reports show increased
propionate levels in brain tissue of AD transgenic mice compared
to wild type controls, an event associated with GM dysbiosis
(Syeda et al., 2018). Although, propionate has some beneficial
effects [e.g., on the BBB (Hoyles et al., 2018)], excessive
propionate alters dopamine, serotonin, and glutamate systems in
a manner similar to that observed in autism spectrum disorders
(El-Ansary et al., 2012; Li et al., 2017).
Fecal samples of children with autism spectrum disorder
present an increased level of propionate (Wang et al., 2012). In
addition, genetic diseases that affect the function of the enzyme
propionyl-CoA carboxylase (such as propionic acidemia) are
characterized by high levels of propionate and high incidence of
dementia (Grunert et al., 2013), while in AD patients, increased
levels of acetate and propionate have been found in saliva samples
compared to healthy controls (Figueira et al., 2016; Yilmaz et al.,
2017). Although, the effects of butyrate and propionate are
still controversially discussed, several data support a role of the
imbalance between butyrate and propionate in the pathogenesis
of AD (Syeda et al., 2018).
Another important pathway connecting the brain and the
GM is the involvement of the immune system (Fung et al.,
2017) studied, e.g., in stroke. According to recent reports, in the
experimental rodent models, stroke leads to dysbiosis (Benakis
et al., 2016; Houlden et al., 2016; Singh et al., 2016; Stanley
et al., 2018) and dysbiosis may have an effect on the course
of the disease (Benakis et al., 2016; Singh et al., 2016; Stanley
et al., 2016). This may be linked to GM-related fine-tuning of the
balance between pro-inflammatory/anti-inflammatory immune
responses primarily in the gut, followed by an infiltration
of immune cells to the CNS after injury. Interestingly, pro-
inflammatory T-helper cell 17 and γδ T cells found in the
ischemic CNS originate from the intestine and the infiltration of
these subpopulations has been linked with unfavorable outcome
(Benakis et al., 2016; Singh et al., 2016).
However, the optimal (in terms of prognosis after stroke)
composition of the GM has not been identified yet and is possibly
difficult to pinpoint. Some findings indicate that the complete
absence (in germ-free mice) or deep antibiotic depletion of
GM can be detrimental, leading to increased infarct volumes
(Singh et al., 2018) or increased mortality not related to lesion
size (Winek et al., 2016). Alterations in GM have also been
identified in stroke patients (Yin et al., 2015; Stanley et al., 2016).
Due to its metabolic capacities, GM can also contribute to the
pathogenesis of the diseases considered as the risk factors of
stroke, like obesity (for review Torres-Fuentes et al., 2017) and
atherosclerosis (Karlsson et al., 2012; Tang et al., 2013) (for
review, see Li and Tang, 2017).
We can conclude that a predominantly pro-inflammatory
GM and the release of neurotoxic substances may negatively
affect brain functions, causing systemic and central inflammation
over decades. This is in support of the recent hypothesis of an
infectious etiology for neurodegenerative diseases, such as AD
(Bhattacharjee and Lukiw, 2013; Little et al., 2014; Maheshwari
and Eslick, 2015; Itzhaki et al., 2016). The substances released
from the GM (i.e., LPS and SCFAs) may be implicated in the
pathogenesis of several neurodegenerative diseases; however,
more data are still needed to clearly understand this gut-brain-
immune interaction.
FROM CONSEQUENCES TO CAUSES:
ACADEMIC AND PRECLINICAL
CONSIDERATIONS
As we have described above, the neurocentric view
entertained as the predominant focus of our effort in treating
neurodegeneration is likely insufficient to ensure successful
therapeutic intervention.
The Lack of Adequate Experimental
Models to Study the Etiology
Investigating the pathophysiological processes behind
neurodegeneration in detail requires the use of animal models.
A plethora of animal models of neurodegeneration exists, and the
nuances of these models are beyond the scope of this manuscript
(for recent reviews, see Gitler et al., 2017; Dawson et al., 2018;
Ransohoff, 2018).
However, two general problems with current models seem to
be particularly widespread and contribute to our limited success
in extrapolating findings from preclinical research to patients.
Firstly, they often fail to fully integrate our understanding
of the etiology of the diseases they are meant to represent,
often being restricted to inducing the disease in a single way,
despite multiple inducing factors being responsible for the
human disease. Secondly, animals used as the model organism
of specific diseases often do not exhibit similar comorbidities
and demographic characteristics (such as age or gender) seen
in human patients. Examples of such problems are the rodent
models of stroke, particularly ones that involve surgical ligation
or occlusion of blood vessels in otherwise healthy, young animals
(van der Worp et al., 2010; Mergenthaler and Meisel, 2012).
Another important issue is the way these models are
characterized. For animal models to be used to study
neurodegeneration, two essential steps must be taken. First,
the validity of the model for the question at hand should be
thoroughly and systematically investigated. This is preferably
done in a multi-centric and multi-disciplinary way to ensure
the generalizability and robustness of the results. Second, the
external (face, construct, and predictive) validity of the model
(Willner, 1984) should be empirically and thoroughly tested,
as well as the inter-rater agreement on, and replicability of, the
model’s characteristics (McKinney and Bunney, 1969). Such
studies aimed at characterizing the model should be very clearly
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and unequivocally separated from experiments using the model
to test hypotheses, such as the effect of an intervention on the
course of the model’s progression.
For these strategies to be successful, research into and using
these models must be conducted in the setting of appropriate,
rigorous, and transparent experimental design and reporting
(Kilkenny et al., 2010; Holman et al., 2016; Percie du Sert et al.,
2017). Beyond that, we should make an active effort to think
of the drawbacks of the models and methods we have used
and how this may restrict or bias the knowledge we gain from
such studies (Garner et al., 2017). Finally, we need a framework
for integrating the knowledge gained from individual studies
using different models and methods to address similar research
questions. Systematic reviews and quantitative meta-analyses,
widely used for knowledge synthesis in clinical research, may be
helpful tools to help us achieve this.
Studying Human Disease in Human
Systems
Although animal models are a powerful tool toward
understanding the etiology of neurodegenerative diseases,
they still present considerable limitations (Jucker, 2010). As
a consequence, there has been little success translating the
knowledge obtained from model organisms to therapeutically
valuable outcomes. This constraint can only be addressed by
studying neurodegenerative diseases directly on humans.
The recent increase in the generation of digital data including
imaging, genotypic, and phenotypic information coupled with a
fast development of computational methods allows us to obtain
new insights from this massive amount of data. Major efforts
from consortiums such as the Alzheimer’s Disease Initiative
(ADNI), the Australian Imaging, Biomarkers & Lifestyle Study
of Ageing (AIBL), the Parkinson’s Progression Markers Initiative
(PPMI) or more recently the United Kingdom Biobank have
made available an unprecedented amount of data, which can be
exploited through the use of big data algorithms.
Having large amounts of information coming from
heterogeneous populations and acquisition systems increases the
power of statistic approaches and reduces the risk of bias. Big data
approaches are inherently limited since in general they cannot be
used to perform causal inference, but rather to find correlations
or associations between variables. However, these correlations
have proven to be an invaluable tool for hypothesis generation,
drug and safety surveillance, disease and treatment heterogeneity
among many other applications (Lee and Yoon, 2017).
Such computational models have been used for example
to build a model of senescence signaling via DNA damage,
insulin-TOR, FoxO3a transcription factors, oxidative stress
response, mitochondrial regulation, and mitophagy using a
systems biology approach (Dalle Pezze et al., 2014). A recent
review of mathematical models in neurodegenerative diseases
reports several mathematical models involving some of the
processes we addressed above, such as energy metabolism and
synaptic plasticity (Lloret-Villas et al., 2017). A multivariate
Bayesian model of biomarker measurements was used to estimate
AD dementia onset age (Bilgel and Jedynak, 2019). Similarly,
multivariate models have been used to relate image based
morphological features to the risk of dementia (Gutierrez Becker
et al., 2018; Cole et al., 2019).
Recent trends in stem cell methods have also opened new
possibilities for human brain cell cultures, which can in turn be
used to model neurodegeneration. Induced pluripotent stem cells
and neural stem cell cultures can now be used to generate human
neurons from human and sometimes patient cells (Abud et al.,
2017; Korhonen et al., 2018). This has been reviewed extensively
elsewhere (Xie and Tang, 2016; Robbins and Price, 2017).
CONCLUSION
Disease is typically defined in juxtaposition to the state of health,
which has been even more generally defined as “a state of
complete physical, mental, and social well-being” (International
Health Conference, 2002). However, in order to characterize a
bodily or mental state as diseased, we need a more practical,
operational definition of the healthy state, characterized in terms
of physiological parameters and defined by the description of the
steady state functioning of the body and its subsystems.
Typically, pathophysiological events of neurodegeneration
are detected through behavioral observations and self-reporting
and subsequently confirmed and classified using neurological
examination and diagnostic imaging. The result of this
diagnostic approach usually reveals typical defining features
for each neurological disease (such as hemorrhage, tumor, or
deformations), that allows the classification of the disorder.
However, these defining characteristics are not necessarily
the root causes of the disease but rather elements of the
disease manifestation or even merely epiphenomena. In addition
to the complex and usually obscure causal relationships
giving rise to brain disorders, a parameter that further
complicates the identification of causation is the widespread
and intricate comorbidities between presumably distinct and
unrelated disorders.
Together, these facts limit the therapeutic potential to treat
the symptoms rather than the causes. The complex causality
chain hinders the early detection and treatment of the root
causes of brain disorders overall and neurodegeneration more
specifically. These limitations highlight the critical need for a
drastic shift of perspective and the improvement of the models
used to investigate and understand neurodegenerative diseases.
Given the complexity of the brain and its disorders,
researchers and clinicians have retreated to a highly segregated
approach, focusing on describing subsets of the symptoms of
each disease and trying to identify mechanistic explanations and
treatments for those symptoms. However, the lack of a holistic
perspective, taking into account the deviations from the default
homeostatic state at an organismal level, renders this endeavor
nearly impossible and doomed to fail.
Importantly, characterizing the expected, default healthy
brain, is a necessary precondition to being able to identify
and meaningfully interpret the deviations from it. Thus,
characterizing and understanding the brain function in health is
of paramount importance in the attempt to understand and treat
the diseased brain.
Frontiers in Neuroscience | www.frontiersin.org 16 July 2019 | Volume 13 | Article 728
fnins-13-00728 July 22, 2019 Time: 17:18 # 17
Castillo et al. Neurodegeneration Revisited
In summary, there is an identifiable need for an
interdisciplinary approach to explore the brain function at
multiple levels, from molecular to systems, while maintaining
a holistic perspective that treats the brain as an element of
a complex system, rather than a separate entity. Using this
approach, fundamental research can proceed hand-in-hand and
maintain a constant dialogue with clinical research, to propose,
improve, and revise current models of health and disease.
We hope that our work inspires the opening of new research
avenues among those interested in understanding and pursuing
the complexities of the “neuro-degenerating” brain focusing
on lifespan processes. Therefore, the proposed etiological paths
and suggestions will be important guidelines for future cross-
discipline research to overcome the translational roadblock and
to develop causative treatments for neurological disorders.
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